Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States

References

• Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503
   PubMed Web of Science ®Google Scholar
• Morrow GR, Roscoe JA, Hickok JT, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology 1998;12(Suppl 4):32-7
   PubMedGoogle Scholar
• Sussman N. Reactions of patients to the diagnosis and treatment of cancer. Anticancer Drugs 1995;6(Suppl 1):4-8
   PubMedGoogle Scholar
• Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-6
   PubMedGoogle Scholar
• Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 2005;13:80-4
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologyTM: Antiemesis. Version 2.2010. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Accessed March 1, 2011]
   Google Scholar
• Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112-16
   PubMed Web of Science ®Google Scholar
• Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2010;10:137-48
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100: 2261-8
   PubMed Web of Science ®Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 2003;98:2473-82
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg GM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Annal Oncol 2006;17:1441-9
   PubMed Web of Science ®Google Scholar
• Rzepecki P, Pielichowski W, Oborska S, et al. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation – single center experience. Transplant Proc 2009;41:3247-3249 doi:10.1016/j.transproceed.2009.07.071
   Google Scholar
• Mattiuzzi GN, Cortes JE, Blamble DA, et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 2010;116:5659-66
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Bonanno V, et al. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 2009;17:205-9
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004;64:1125-32
   PubMed Web of Science ®Google Scholar
• Aloxi injection (palonosetron hydrochloride) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc, 2009
   Google Scholar
• López-Jiménez J, Martín-Ballesteros E, Sureda A, et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006;91:84-91
   PubMed Web of Science ®Google Scholar
• Weiner MG, Livshits A, Carozzoni C, et al. Derivation of malignancy status from ICD-9 codes. American Medical Informatics Association (AMIA) 2003 Symposium Proceedings: 1050
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95
   PubMed Web of Science ®Google Scholar
• Tremblay P, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003;21:2147-55
   PubMed Web of Science ®Google Scholar
• Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxtryptamine type 3 receptor antagonist according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-11
   PubMed Web of Science ®Google Scholar
• Abali H, Celik I. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Cancer Invest 2007;25:135-9
   PubMed Web of Science ®Google Scholar
• Walsh T, Morris AK, Holle LM, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant 2004;34:963-8
   PubMed Web of Science ®Google Scholar
• Tan M, Xu R, Seth R. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study. Curr Med Res Opin 2004;20:879-82
   PubMed Web of Science ®Google Scholar
• Fox-Geiman MP, Fisher SG, Kiley K, et al. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 2001;7:596-603
   PubMed Web of Science ®Google Scholar
• Slaby J, Trneny M, Prochazka B, et al. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 2000; 47:319-22
   PubMed Web of Science ®Google Scholar
• Spitzer TR, Friedman CJ, Bushnell W. Double-blind randomized parallel-group study on the efficacy safety of oral granisetron oral ondansetron in the prophylaxis of nausea vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Trans 2000;26:203-10
   PubMed Web of Science ®Google Scholar
• Orchard PJ, Rogoscheske J, Burns L, et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 1999;5:386-93
   PubMedGoogle Scholar
• Feinberg B, Gilmore J, Haislip S, et al. Likelihood of a subsequent chemotherapy induced nausea and vomiting (CINV) event in patients receiving moderately or highly emetogenic chemotherapy (MEC/HEC). Presented at the 2010 ISPOR European Congress, November 6-9, 2010; Prague, Czech Republic
   Google Scholar
• Schwartzberg L, Szabo S, Gilmore J, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderate or highly emetogenic chemotherapy (LEC/MEC/HEC). Curr Med Res Opin 2011;27:837-45 doi: 10.1185/03007995.2011.556603
   PubMed Web of Science ®Google Scholar
• Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626:193-9 doi:10.1016/j.ejphar.2009.10.002
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society, 2010
   Google Scholar
• Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008;16:201-8
   PubMed Web of Science ®Google Scholar
• Osoba D, Zee B, Pater J, et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:116-23
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States. Blood 2006;107:265-276 doi: 10.1182/blood-2005-06-2508
   PubMed Web of Science ®Google Scholar
• Benjamin M, Reddy S, Brawley OW. Myeloma and race: a review of the literature. Cancer Metastasis Rev 2003;22:87-93
   PubMed Web of Science ®Google Scholar